High TGF-β1 expression usually indicated an immune-suppressive micro-environment, which suggested that the tissues of vascular remodeling might lack proper immune surveillance, e.g., increased infiltration of macrophages or regulatory T cells, suggesting that targeting the immune system using small molecular chemicals or mono-antibody might also be useful to treat hypertension-related complications at an early stage. This evidence concerns the gene TGFB1 and hypertensive disorder.